3-(N-(4-cyanophenyl)sulfamoyl)benzoic acid | 365562-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(N-(4-cyanophenyl)sulfamoyl)benzoic acid
• 英文别名: 3-[(4-Cyanophenyl)sulfamoyl]benzoic acid
• CAS: 365562-50-1
• 化学式: C₁₄H₁₀N₂O₄S
• 分子量: 302.31
• InChiKey: CXOVXOCVZZFPRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(N-(4-cyanophenyl)sulfamoyl)benzoic acid 、 对氨基苯腈 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以67%的产率得到N-(4-cyanophenyl)-3-(N-(4-cyanophenyl)sulfamoyl)benzamide
  参考文献：
  名称：

  Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors

  摘要：

  Inhibitors of sirtuin-2 deacetylase (SIRT2) have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the neuroprotective sulfobenzoic acid scaffold and improving their pharmacology. To achieve that goal, 176 analogues were designed, synthesized, and tested in deacetylation assays against the activities of major human sirtuins SIRT1-3. This screen yielded 15 compounds with enhanced potency for SIRT2 inhibition and 11 compounds having SIRT2 inhibition equal to reference compound AK-1. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. These candidates were subjected to a dose-response bioactivity assay, measuring an increase in alpha-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested. These bioactive compounds were subsequently tested in a tertiary polyglutamine aggregation assay, which identified five inhibitors. ADME properties of the bioactive SIRT2 inhibitors were assessed, which revealed a significant improvement of the pharmacological properties of the new entities, reaching closer to the goal of a clinically-viable candidate. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.02.003
• 作为产物：
  描述：

  苯甲酸 在 吡啶 作用下， 以 乙酸乙酯 为溶剂， 反应 4.0h， 生成 3-(N-(4-cyanophenyl)sulfamoyl)benzoic acid
  参考文献：
  名称：

  Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors

  摘要：

  Inhibitors of sirtuin-2 deacetylase (SIRT2) have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the neuroprotective sulfobenzoic acid scaffold and improving their pharmacology. To achieve that goal, 176 analogues were designed, synthesized, and tested in deacetylation assays against the activities of major human sirtuins SIRT1-3. This screen yielded 15 compounds with enhanced potency for SIRT2 inhibition and 11 compounds having SIRT2 inhibition equal to reference compound AK-1. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. These candidates were subjected to a dose-response bioactivity assay, measuring an increase in alpha-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested. These bioactive compounds were subsequently tested in a tertiary polyglutamine aggregation assay, which identified five inhibitors. ADME properties of the bioactive SIRT2 inhibitors were assessed, which revealed a significant improvement of the pharmacological properties of the new entities, reaching closer to the goal of a clinically-viable candidate. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.02.003

文献信息

• Benzamide Compounds and Related Methods of Use
  申请人：Northwestern University

  公开号：US20150025235A1

  公开（公告）日：2015-01-22

  Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

  苯甲酰胺化合物及其衍生物可用于选择性抑制SIRT2酶和/或治疗亨廷顿病。
• Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer
  作者：Chenfan Li、Xiaoli Han、Qiuxia Yan、Yang Ji、Rongyu Zhang、Dazhong Yuan、Fulian Yang、Jianlong Wang、Meng Wu、Jinming Zhou

  DOI：10.1021/acs.jmedchem.3c01668

  日期：2024.3.14

  Androgen receptor (AR) antagonists play important roles in the treatment of castration-resistant prostate cancer (CRPC). The glucocorticoid receptor (GR) upregulation leads to drug resistance for clinically used antiandrogens. Therefore, blocking AR/GR signaling simultaneously has become an efficient strategy to overcome the drug resistance of CRPC. Our previous work indicated that Z19 could inhibit

  雄激素受体（AR）拮抗剂在去势抵抗性前列腺癌（CRPC）的治疗中发挥着重要作用。糖皮质激素受体（GR）上调会导致临床使用的抗雄激素产生耐药性。因此，同时阻断AR/GR信号已成为克服CRPC耐药性的有效策略。我们之前的工作表明Z19可以抑制AR和GR的活性。在此，我们优化了Z19的结构，并将GA32鉴定为有效的 AR/GR 双重抑制剂。 GA32有效降低 AR/GR 下游基因的 mRNA 和蛋白质水平。 GA32在体外和体内均能有效抑制恩杂鲁胺耐药性 CRPC 的增殖。 GA32可以直接与AR和GR结合，并且预测的GA32与AR/GR的结合模式表明GA32与AR或GR激素结合口袋结合。这项工作提供了一种具有双重 AR/GR 抑制活性的潜在先导化合物，以克服 CRPC 的耐药性。
• US9371277B2
  申请人：——

  公开号：US9371277B2

  公开（公告）日：2016-06-21
• US9533947B2
  申请人：——

  公开号：US9533947B2

  公开（公告）日：2017-01-03
• US9890117B2
  申请人：——

  公开号：US9890117B2

  公开（公告）日：2018-02-13